Dr. Wen-Hsuan Chang, AcuraStem’s Head of Target Validation to present at the 33rd International Symposium on ALS/MND
Dec 5, 2022, 1:10 PM
Dr. Wen-Hsuan Chang, AcuraStem’s Head of Target Validation to present at the 33nd International Symposium on ALS/MND being held virtually on December 6-9, 2022. Dr. Chang will detail AcuraStem’s development program leveraging its best-in-class iNeuroRx® platform, composed of patient-derived disease models that accurately recapitulate UNC13A pathology, to develop novel and potent UNC13A antisense oligonucleotide (ASO) drug candidates. UNC13A is one of the most significant genetic risk factors for ALS and FTD.
Scientific Cofounder, Dr. Justin K. Ichida, and Head of Research, Dr. Wen-Hsuan Chang to present at the 32nd International Symposium on ALS/MND, being held virtually on December 7-10, 2021
Dec 6, 2021, 5:01 PM
AcuraStem will present posters at the 32nd International Symposium on ALS/MND.
Sep 18, 2019, 3:09 PM
One of the compounds in a series under development by AcuraStem for ALS, was administered to a neuronal cell line derived from a patient with CMT2A, and showed improved cell survival resulting in the identification as a promising new, preclinical drug candidate for CMT2A
Jan 15, 2019, 11:20 AM
MDA has awarded an MVP grant totaling $300,000 over two years to AcuraStem to support preclinical development of a novel small molecule therapeutic for ALS.
CMTRF Inks Milestone-Driven Partnership with AcuraStem to Repurpose Established Drugs for the Treatment of Charcot-Marie-Tooth Disease
Dec 20, 2018, 10:38 AM
CMT Research Foundation announced today it has entered into a collaborative research partnership with AcuraStem to test thousands of compounds aimed at producing effective treatments for Charcot-Marie-Tooth disease.
Nov 8, 2018, 4:12 PM
Academy Award-winning actress Renee Zellweger encourages the audience to learn more about AcuraStem’s research work in amyotrophic lateral sclerosis (ALS) at the 16th Annual ALS Association Walk to Defeat ALS at Exposition Park in Los Angeles
Apr 20, 2018, 12:58 PM
Dr. Justin K. Ichida was recently profiled by Seema Sharma with Mendeley as a part of their series on stem cells and regenerative medicine. In the interview Dr. Ichida discusses his research, career path, and shares advice for those seeking a transition from postdoctoral to tenure-track.
Feb 22, 2018, 2:45 PM
In a recently published article for The Hollywood Reporter, Acurastem co-founder Dr. Justin Ichida shares a personal account of how famed publicist and ALS patient Nanci Ryder, and her friends in the fight, have helped to accelerate groundbreaking in vitro research being done at his USC-based laboratory (results of which were published in a recent Nature Medicine article).
Feb 13, 2018, 10:36 PM
AcuraStem co-founder Justin Ichida co-authored the groundbreaking research paper "Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons," published in Nature Medicine February 5.
California has confidence in AcuraStem. AcuraStem is one of 90 companies selected for a unique California tax benefit.
Nov 16, 2017, 12:00 PM
The Governor’s Office of Business and Economic Development (GO-Biz) announced that the California Competes Tax Credit (CCTC) committee approved $69 million in tax credits for 90 companies projected to create 6,236 jobs and make $1.2 billion worth of new capital equipment investments across California.